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Abstract The effect of some antidepressants co-administered
with EMD386088 in the modified forced swim test in rats was
investigated. Additionally, the pharmacokinetics, metabolic
stability, and the effect of EMD386088 on P450 cytochromes
were determined. Intraperitoneal (i.p.) coadministration of
EMD386088 (2.5 mg/kg) and imipramine (15 mg/kg),
reboxetine (5 mg/kg), moclobemide (10 mg/kg), or bupropion
(10 mg/kg) evoked significant antidepressant-like activity,
whereas no effect was observed after joint administration of
EMD386088 with s-citalopram (10 mg/kg). Pharmacokinetic
in vivo investigation showed a rapid absorption of
EMD386088 (2.5 and 5 mg/kg) with t1/2 = 67 min (t-
max = 5 min). Large volume of distribution (Vd/F = 102 L/
kg) indicated its penetration into peripheral compartments.
The most active coadministration of EMD386088 (2.5 mg/
kg) with imipramine (15 mg/kg) resulted in slower absorption
of the compound (Cmax = 60 min) and decrease in the volume
of distribution (Vd/F = 32.2 L/kg). EMD386088 penetrates the
blood–brain barrier with a high brain/plasma ratio of about 19
(2.5 mg/kg) and 7.5 for coadministration with imipramine.
The in silico and in vitro studies on EMD386088 metabolic
stability showed the dehydrogenation of tetrahydropyridine
moiety as its main metabolic pathway. EMD386088 did not
influence on CYP3A4 activity, and it has been classified as a
very weak CYP2D6 inhibitor (IC50 = 2.25 μM). The results
obtained from the forced swim test in rats indicate that an
activation of 5HT6 receptor may facilitate antidepressant-like
activity of some antidepressants. The pharmacokinetic results
suggest that the interaction between EMD386088 and imipra-
mine could not have been pharmacokinetic in nature.
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Introduction
The serotonin-6 (5-HT6) receptors belong to serotonin recep-
tors that are positively coupled to the Gs protein and stimulate
adenylate cyclase activity (Monsma et al. 1993; Ruat et al.
1993; Plassat et al. 1993). Their distribution in the limbic areas
and ability for different neurotransmission system modula-
tions (i.e., cholinergic, glutamatergic, and γ-aminobutyric ac-
id-ergic (GABAergic)) indicate that 5-HT6 receptors are in-
volved in mood and cognitive processes (Ward et al. 1995;
Gérard et al. 1996; Yoshioka et al. 1998; Takamori et al.
2001). Literature preclinical data show that 5-HT6 receptors
have an important function in regulating mood since both
agonists/partial agonists (i.e., WAY181187, WAY208466,
EMDT, ST1936) and antagonists (i.e., SB271046,
SB258585, SB399885) of these receptors possess
antidepressant-like activity (Svenningsson et al. 2007;
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Wesołowska et al. 2007; Wesołowska 2008; Hirano et al.
2009; Carr et al. 2011; Nikiforuk et al. 2011; Jastrzębska-
Więsek et al. 2014, 2015). At present, it is difficult to indicate
molecular mechanisms through which both activation and
blockade of these receptors are able to evoke the same
antidepressant effect observed in animals.
The compound EMD386088 has been presented by
Mattsson et al. (2005) as a 5-HT6 receptor agonist
(EC50 = 1.0 nM). Recently obtained in vitro results demon-
strated that EMD386088 behaves as a potent 5-HT6 receptor
partial agonist (Jastrzębska-Więsek et al. 2013). It also has no
affinity for α1-, α2-, and β1-adrenoceptors, dopamine D2, do-
pamine D3, GABAA, opioidμ receptors, and serotonin (5-HT)
transporter (Jastrzębska-Więsek et al. 2013). Previous find-
ings have indica ted that EMD386088 exer ts an
antidepressant-like effect after acute, sub-chronic (three times
during 24 h in the forced swim test (FST)) and chronic (once
daily for 14 days) systemic administration in the olfactory
bulbectomy model in rats (Jastrzębska-Więsek et al. 2015).
Previously obtained data confirm the importance of dopami-
nergic system activation in antidepressant-like activity of
EMD386088 after acute administration, since this effect, ob-
served in the FST, was abolished by the preferential D1- and
D2-like receptor subfamily antagonists SCH23390 and
sulpiride, respectively (Jastrzębska-Więsek et al. 2016). In
the ex vivo neurochemical studies, EMD386088 changed on-
ly the dopamine metabolism and activity of dopaminergic
system in all investigated brain structures, i.e., hippocampus,
nucleus accumbens, and striatum but there was not observed
effect on the noradrenergic- or serotonergic system. In func-
tional in vitro study, EMD386088 showed significant affinity
for dopamine transporter (DAT). These all data confirm that
antidepressant-like activity of EMD386088 in FST may be
connected with the activation of dopaminergic system, while
neither noradrenergic nor serotonergic ones are involved in its
effect (Jastrzębska-Więsek et al. 2016).
We designed a modified version of FST in rats to evaluate
the interaction between EMD386088 and some antidepres-
sants with a different mechanism of action. Antidepressant
drugs, chosen for the study, included the 5-HT/noradrenaline
reuptake inhibitor imipramine, the selective noradrenaline re-
uptake inhibitor reboxetine, the selective 5-HT reuptake inhib-
itor s-citalopram, the dopamine reuptake inhibitor bupropion,
and the monoamine oxidase-A inhibitor moclobemide. All
compounds were given as non-active doses, chosen from the
results of our earlier studies (Wesołowska and Nikiforuk
2007; Jastrzębska-Więsek et al. 2015).
Since pharmacokinetic studies are an important part of tests
performed for new compounds with proven biological activi-
ty, we decided to investigate the pharmacokinetic profile of
EMD386088 through a single i.p. administration and by co-
administration with imipramine. We also chose to determine
in vitro, the effect of EMD386088 on recombinant
isoenzymes CYP3A4 and CYP2D6 of P450 cytochrome,
since their potential inhibition could be involved in antide-
pressant effects observed in FST. Metabolic stability of
EMD386088 was also evaluated in silico by MetaSite soft-
ware and in vitro using rat liver microsomes (RLMs).
Material and methods
Animals
The experiments were performed on male Wistar rats (250–
300 g) purchased from Charles River Laboratories
(Germany). The animals were housed for a period of 6 days
in polycarbonate Makrolon type 3 cages (dimensions
26.5 × 15 × 42 cm) in an environmentally controlled room
(ambient temperature 21 ± 2 °C; relative humidity 50–60%;
12:12 light:dark cycle, lights on at 8:00), in groups of four rats.
Standard laboratory food (LSM-B) and filtered water were
freely available.
In behavioral experiments, animals were assigned random-
ly to treatment groups. All the tests were performed by two
observers unaware of the treatment applied between 9:00 and
14:00 on separate groups of animals.
A pharmacokinetic study was carried out for EMD386088
and imipramine following their single and combined i.p. ad-
ministrations to rats. Blood samples were collected at 0 min
(predose), 5 min, 15 min, 30 min, 60 min, 120 min, and
240 min after injections. The blood was collected from right
ventricle under anesthesia using a mixture of ketamine
(50 mg/kg)/xylasine (8 mg/kg) in the ratio of 3:1, and
0.025 mL of a mixture for 10 g body weight was injected
i.p. 10 min before planned blood collection. Blood and brain
samples were collected under general anesthesia induced by
i.p. injections of ketamine (50 mg/kg)/xylasine (8mg/kg). The
blood samples were taken into heparinized tubes, immediately
centrifuged at 3500 rpm for 10min, and plasma was collected.
After the blood was drawn, the rat’s spinal cord was cut and
the cerebral tissue was removed, and after dissection washed
in PBS saline. The brain and plasma samples were immedi-
ately frozen at − 80 °C for LC/MS/MS analysis.
Procedures involving animals and their care were con-
ducted in accordance with current European Community
and Polish legislation on animal experimentation.
Additionally, all efforts were made to minimize animal
suffering and to use only the number of animals necessary
to produce reliable scientific data. The experimental pro-
tocols and procedures described in this manuscript were
approved by the IV Local Ethics Commission in Warsaw
(no 40/2008) and were in accordance with EU Directive
2010/63/EU and the 1996 NIH Guide for the Care and
Use of Laboratory Animals.
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Drugs
The following drugs were used: 5-chloro-2-methyl-3-(1,2,3,6-
tet rahydro-4-pyridinyl)-1H- indole hydrochlor ide
(EMD386088) and s-citalopram were synthesized by
Adamed (Pieńków, Poland), imipramine (Sigma Aldrich,
Germany), moclobemide (Sigma Aldrich, Germany),
reboxetine (Ascent, UK), bupropion (Sigma Aldrich,
Germany), xylazine (Sigma-Aldrich, USA), ketamine
(Vetoquinol, Poland). All drugs were dissolved in distilled
water immediately before administration in a volume of
2 mL/kg. All the compounds were administered intraperitone-
ally (i.p.). EMD386088, imipramine, and s-citalopram were
given 30 min before the test, while the remaining compounds
were injected 60 min before. Control animals received vehicle
according to the same schedule.
Behavioral experiments
Forced swim test in rats
The experiment was carried out according to the modified by
Detke et al. (1995) method of Porsolt et al. (1978). On the first
day of an experiment, the animals were gently individually
placed in Plexiglas cylinders (40 cm high, 18 cm in diameter)
containing 30 cm of water maintained at 23–25 °C for 15 min.
On removal from water, the rats were placed for 30 min in a
Plexiglas box under 60-W bulb to dry. On the following day
(24 h later), the rats were re-placed in the cylinder and the total
duration of immobility, swimming, and climbing was record-
ed during the whole 5-min test period. The swimming behav-
ior entailed active swimming motions, e.g., moving horizon-
tally around in the cylinder. Climbing activity consisted of
upward directed movements of the forepaws along the side
of the swim chamber, and immobility was assigned when no
additional activity was observed other than that necessary to
keep the rat’s head above the water (Detke et al. 1995). Fresh
water was used for each animal.
Open field test in rats
The experiment was performed using Motor Monitor System
(Campden Instruments, Ltd., UK) consisted of two
SmartFrame Open Field stations (40 × 40 × 38 cm) with
16 × 16 beams, located in sound attenuating chambers and
connected to PC software by control chassis. Individual
vehicle- or drug-injected animals were gently placed in the
center of the station. An automated motor monitor system
recorded ambulation (the number of crossings in X and Y
axis), the number of rearing episodes, and total distance cov-
ered by a rat for 5 min.
Statistical analysis
The data of behavioral studies were evaluated using two-way
analysis of variance (ANOVA) followed by Bonferroni’s post
hoc test, p < 0.05 was considered significant.
Pharmacokinetic study in rats
Pharmacokinetic parameters were calculated by a non-
compartmental approach from the average concentration
values, using Phoenix WinNonlin software (Certara,
Princeton, NJ 08540 USA). First order elimination rate
constant (λz) was calculated by linear regression of time
versus log concentration. Next, the area under the mean
plasma and brain concentration versus time curve
(AUC0 → t) was estimated using the log-linear trapezoidal
rule (Eq. 1), where Cn is the concentration of last sam-
pling of the compound.
AUC0→t ¼ ∑ni¼1 Ci þ Ciþ1ð Þ=2ð Þ∙ tiþ1−tið Þ þ Cn=λz ð1Þ
Area under the first-moment curve (AUMC0→t) was esti-
mated by calculation of the total area under the first-
moment curve using the Eq. 2, where tn is the time of last
sampling.
AUMC0→t ¼ ∑
n
i¼1
ti∙Ci þ tiþ1∙Ciþ1ð Þ=2ð Þ∙ tiþ1−tið Þ
þ tn∙Cnð Þ=λz þ Cn=λ2z ð2Þ
Mean residence time (MRT) was calculated as follows:
MRT ¼ AUMC0→t
AUC0→t
ð3Þ
Total clearance (ClT) was calculated as follows:
ClT ¼ F⋅Di:p:AUC0→t ð4Þ
Volume of distribution (Vd) was calculated as:
Vd ¼ F⋅Di:p:λz⋅AUC0→t ð5Þ
where Di.p. is an i.p. dose of EMD386088.
Analytical method
The quantification of studied compounds in plasma and
brain samples was done using HPLC Agilent 1100 system
(Agilent Technologies, Waldbronn, Germany) coupled to
the triple quadrupole mass spectrometer API 2000
(ABSciex, Framingham, Massachusetts, USA) equipped
with an electrospray ion source. After preparation, the
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samples were injected (20 μL) onto XBridge C18
(2 .1 mm × 30 mm, 3 .5 μm, Wate r s , Mi l fo rd ,
Massachusetts, USA) analytical column. The mobile
phase consisted of ACN with 0.1% formic acid (A) and
water with 0.1% formic acid (B) were delivered in gradi-
ent elution started with 90% of eluent B, increasing dur-
ing 2 min to 90% of eluent A, maintained to 3 min, and
then returned during 5 min to 90% of eluent B, and main-
tained 90% of eluent B during 5 min at a flow rate of
300 μL/min. The total time of analysis was 15 min.
Electrospray ionization process was performed in positive
ionization and the data acquisition was carried out in mul-
tiple reaction monitoring mode (MRM) for EMD386088
and its internal standard (nebivolol). The ion spray source
settings were as follows: spray voltage: 5 kV, heater tem-
perature: 350 °C, curtain gas: 15 psi, source gas 1: 35 psi,
source gas 2: 10 psi. The ions measured were m/z 247.3
(Q1) and m/z 168.2 (Q3) for EMD386088, and m/z 406.2
(Q1) and m/z 151.1 (Q3) for IS.
Preparation of standard solutions
An amount of 10mg of EMD386088 was accurately weighted
and quantitatively transferred into the 10-mL volumetric flask
using MeOH. After the salts dissolving, flask was filled to the
10-mL mark with MeOH obtaining 1 mg/mL of an analyte.
Further dilutions were performed using MeOH to prepare
working standard solutions of the analyte at the following
concentrations: 0.025, 0.05, 0.1, 0.25, 0.5, 1.0, 2.5, 5.0, 10,
25, and 50 μg/mL for calibration curve samples (CC) and
0.025, 0.075, 2.2, and 4.5 μg/mL for quality control samples
(QC). To prepare samples for calibration curve or quality con-
trol samples, 45 μL of matrix (plasma or brain homogenate)
were spiked with 5 μL of an internal standard solution
obtaining the final concentration of 100 ng/mL and 5 μL of
standards working solutions at needed CC or QC concentra-
tion levels. After standards solution addition, samples were
mixed and purified.
Sample preparation
A sample volume of 50 μL of plasma or brain homoge-
nate was transferred into the clean Eppendorf tube and
spiked with 5 μL of IS solution (1 μg/mL) obtaining the
final concentration of 100 ng/mL. After 5 min of mixing
(1500 rpm), proteins were precipitated using 150 μL
ACN. After 10 min of samples shaking (1500 rpm), the
incubation step was performed (10 min, 4 °C). Next, sam-
ples were centrifuged (10,000 rpm, 10 min, 4 °C) and the
supernatant was transferred into chromatographic vial for
LC/MS/MS analysis. The brain homogenate was prepared
maintaining the tissue: phosphate-buffered saline (PBS) at
a ratio of 1:5. The homogenization was carried out
employing IKA® T10 Basic ULTRA-TURRAX disperser
(IKA Werke GmbH & Co. KG, Staufen, Germany). After
homogenization, 50 μL of sample was collected for fur-
ther preparation. All samples were stored on ice during
the preparation process.
Metabolic stability of EMD386088 investigations
In silico investigation
The in silico study was performed byMetaSite 5.1.1 provided
by Molecular Discovery Ltd. The highest metabolism proba-
bility sites and the prediction of the structures of metabolites
were analyzed during this study by liver computational model
(Cruciani et al. 2005).
In vitro investigation
Commercial, pooled, rat liver microsomes (RLMs) were pur-
chased from Sigma-Aldrich (St. Louis, USA). The biotrans-
formations were carried out using 1 mg/mL of RLMs in
200 μL of reaction buffer containing 0.1 M Tris-HCl
(pH 7.4) and EMD386088 with final volume 50 μM. The
reactionmixture was preincubated at 37 °C for 5 min and then,
the reaction was initiated by adding 50 μL of NADPH
Regeneration System (Promega, Madison, WI, USA). The
reaction was terminated after 30 or 120 min by the addition
of 200 μL of coldmethanol. Themixture was next centrifuged
at 14000 rpm for 15 min and the UPLC/MS analysis of the
supernatant was performed. Mass spectra was recorded on
UPLC/MS system consisted of a Waters Acquity UPLC
(Waters, Milford, USA), coupled to a Waters TQDmass spec-
trometer (electrospray ionization mode ESI-tandem
quadrupole).
Influence on recombinant human CYP3A4 and 2D6 P450
cytochromes
The luminescent CYP3A4 P450-Glo™ and CYP2D6 P450-
Glo™ assays and protocols were provided by Promega
(Madison, WI, USA) (Cali et al. 2006). The reference drugs
ketoconazole (KE) and quinidine (QD) were obtained from
Sigma-Aldrich (St. Louis, USA). The enzymatic reactions
were performed in white polystyrene, flat-bottom Nunc™
MicroWell™ 96-Well Microplates (Thermo Scientific,
Waltham, MA USA). The luminescence signal was measured
with a microplate reader in luminescence mode (EnSpire,
PerkinElmer, Waltham, MA USA). The IC50 values of KE
and QD were determined and calculated as we described pre-
viously (Sadek et al. 2016). The final concentrations of EMD
386088 were similar for both CYP3A4 and CYP2D6 assays
from 0.025 to 25 μM.
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Results
Interaction between EMD386088 and antidepressant
drugs in the FST
The results presented in Fig. 1 show that a concomitant ad-
ministration of non-active doses of EMD386088 (2.5 mg/kg)
and imipramine (15 mg/kg) showed in two-way ANOVA
analysis of variance significant decreasing of immobility time
(F(1,24) = 23.628, p < 0.0001) as well as increasing of
climbing behavior (F(1,24) = 12.444, p < 0.01) respectively
to the vehicle control and single administration of
EMD386088 or imipramine (Fig. 1a). EMD386088
(2.5 mg/kg) co-administered with the non-active doses of
reboxetine (5 mg/kg, Fig. 1b, (F(1,25) = 6.5843, p < 0.05)),
moclobemide (10 mg/kg, Fig. 1c, (F(1,25) = 4.8193,
p < 0 . 05 ) ) o r bup rop i on (10 mg /kg , F i g . 1d ,
(F(1,26) = 6.0071, p < 0.05)) provoked statistically significant
interactions only in an anti-immobility effect. A combination
of non-active doses of EMD386088 (2.5 mg/kg) and s-
citalopram (10 mg/kg) did not produce any significant effect
on immobility time, climbing behavior and swimming time in
the FST (Fig. 1e, (F(1,24) = 1.9267, NS).
Effects of EMD386088 and the antidepressant drugs
administered alone or jointly in the OF test
The compound EMD386088 (2.5 mg/kg) co-administered
with imipramine (15 mg/kg) significantly reduced total dis-
tance only evaluated by the OF test, whereas the other param-
eters, i.e., rearings, X and Y ambulation remained unchanged
(Table 1). Other antidepressants given jointly with
EMD386088 did not change animals’ locomotor activity in
that test. Antidepressants and EMD386088 administered
alone had no effect on the exploratory activity in the OF test,
except of s-citalopram (10 mg/kg) that significantly reduced
total distance (Table 1).
Fig. 1 Effects of EMD386088 and antidepressants given alone or in
combination in the modified FST in rats. a Effects of EMD386088 and
imipramine in the FST. b Effects of EMD386088 and reboxetine in the
FST. c Effects of EMD386088 and moclobemide in the FST. d Effects of
EMD386088 and bupropion in the FST. e Effects of EMD386088 and s-
citalopram in the FST. EMD386088, imipramine, and s-citalopram were
injected i.p. 30 min, while reboxetine, moclobemide, and bupropion were
given i.p. 60 min before the test. Values represent the mean ± SEM and
were analyzed by two-way ANOVA followed by Bonferroni’s post hoc
test: *p < 0,05, **p < 0.01, ***p < 0.001relative to respective vehicle
group; ###p < 0.001, ####p < 0.0001 relative to respective group receiv-
ing non-active dose of respective antidepressant drug without
EMD386088, N = 6–8
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Pharmacokinetic study
The plots of mean plasma and brain concentrations versus
time profile for EMD386088 administered alone at doses of
2.5 and 5 mg/kg and jointly 2.5 mg/kg with imipramine
(15 mg/kg) are depicted in Fig. 2.
The pharmacokinetic parameters for EMD386088 calculated
by non-compartmental approach are given in Table 2. The com-
pound was eliminated relatively quickly from rats’ body and its
terminal half-life time was about 70 min. EMD386088 showed a
large volume of distribution (102 L/kg) that indicates its ability
for penetration to the deep compartment. EMD386088 reached
the maximum concentration in the blood within 5 min.
Coadministration of the compound with imipramine increased
the time to reach the maximum concentration (tmax = 60 min),
increased three times the area under the concentration-time curve
(AUC), and decreased three times its volume of distribution. The
investigated compound exhibited significant distribution to brain
which is in agreement with its high volume of distribution but
exposition of EMD386088 in the brain after i.p. administration is
slow (tmax = 120 min) (Table 2). The brain to plasma ratio cal-
culated on the basis of AUC0 → t values is very high, ca. 19.
Coadministration of EMD386088 with imipramine decreased
about two times the brain/plasma ratio (Table 3).
Metabolic stability of EMD386088 study
The metabolic stability of EMD386088 was examined first in
silico by using MetaSite software (Cruciani et al. 2005). The
plot of MetSite predictions for the most probable sites of
Table 1 Effect of EMD386088, imipramine, s-citalopram, reboxetine, moclobemide, and bupropion given alone or in combination on the rat
locomotor activity measured in the OF test
Treatment Dose (mg/
kg)
Exploratory activity
Total distance (cm) Rearings Ambulation X Ambulation Y
Vehicle + Vehicle 0 + 0 2790 ± 174 72 ± 10 291 ± 40 275 ± 30
Vehicle + imipramine 0 + 15 2212 ± 332 54 ± 3 209 ± 37 203 ± 41
Vehicle + EMD 386088 0 + 2.5 2677 ± 232 90 ± 3 261 ± 29 261 ± 31
imipramine + EMD
386088
15 + 5 1909 ± 125*
F(1,20) = 0.4677;
p = 0.502
89 ± 9
F(1,20) = 1.0969;
p = 0.307
165 ± 25
F(1,20) = 0.0383;
p = 0.847
157 ± 30
F(1,20) = 0.2249;
p = 0.640
Vehicle + Vehicle 0 + 0 2790 ± 174 72 ± 10 291 ± 40 275 ± 30
Vehicle + s-citalopram 0 + 10 1935 ± 121* 64 ± 12 197 ± 15 179 ± 19
Vehicle + EMD 386088 + 0 + 2.5 2677 ± 232 90 ± 3 261 ± 29 261 ± 31
s-citalopram + EMD
386088
10 + 2.5 2160 ± 173
F(1,20) = 0.8898;
p = 0.357
69 ± 8
F(1,20) = 0.5108;
p = 0.483
228 ± 26
F(1,20) = 1.1364;
p = 0.299
232 ± 27
F(1,20) = 1.5337;
p = 0.230
Vehicle + Vehicle 0 + 0 3102 ± 434 94 ± 13 274 ± 40 281 ± 38
Vehicle + reboxetine 0 + 5 2196 ± 74 84 ± 6 221 ± 16 220 ± 12
Vehicle + EMD 386088 + 0 + 2.5 2721 ± 196 91 ± 4 262 ± 28 261 ± 31
reboxetine + EMD 386088 5 + 2.5 2651 ± 265
F(1,20) = 1.8780;
p = 0.186
87 ± 6
F(1,20) = 0.0431;
p = 0.838
267 ± 37
F(1,20) = 0.8117;
p = 0.378
269 ± 34
F(1,20) = 1.6607;
p = 0.212
Vehicle + Vehicle 0 + 0 3102 ± 434 94 ± 13 274 ± 40 281 ± 38
Vehicle + moclobemide 0 + 10 2160 ± 183 62 ± 3 200 ± 26 192 ± 23
Vehicle + EMD 386088 + 0 + 2.5 2644 ± 220 89 ± 4 262 ± 35 267 ± 37
moclobemide + EMD
386088
10 + 2.5 2405 ± 168,
F(1,19) = 1.5830;
p = 0.223
69 ± 6
F(1,19) = 0.5090;
p = 0.484
229 ± 25
F(1,19) = 0.4146;
p = 0.527
244 ± 30
F(1,19) = 1.0302;
p = 0.322
Vehicle + Vehicle 0 + 0 2696 ± 308 71 ± 7 251 ± 31 270 ± 40
Vehicle + bupropion 0 + 10 3083 ± 229 83 ± 9 284 ± 31 301 ± 35
Vehicle + EMD 386088 + 0 + 2.5 2722 ± 145 92 ± 9 263 ± 28 262 ± 23
Bupropion + EMD
386088
10 + 2.5 3284 ± 306
F(1,20) = 0.1094;
p = 0.744
85 ± 6
F(1,20) = 2.0155;
p = 0.171
365 ± 47
F(1,20) = 0.9526;
p = 0.341
334 ± 30
F(1,20) = 0.3473;
p = 0.562
EMD386088, imipramine, and s-citalopram were injected i.p. 30 min, while reboxetine, moclobemide and bupropion were given i.p. 60 min before the
test. Values represent the mean ± SEM during 5-min test session compared to the respective group: vehicle + vehicle group *p < 0.05, NS not significant
(two-way ANOVA is followed by the Bonferroni’s post hoc test), N = 6
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metabolism of EMD386088 by liver computational model is
shown in Fig. 3.
The darker gray color of the marked functional group indi-
cates its higher probability to be involved in the metabolism
pathway. The black circle marked the site of EMD386088
involved in metabolism with the highest probability.
MetaSite is also able to predict the most probably structures
of metabolites. The metabolites ranking and the structures of
10 metabolites which may occur with the highest probability
(> 50%) are presented on Figs. 4 and 5.
The metabolic stability of EMD386088 was also evaluated
in vitro using RLMs. A full scan chromatogram of the reaction
mixture after 30 min of EMD386088 incubation showed the
presence of one metabolite M-I, whereas after 120 min its four
metabolites (M I-IV) occurred (Figs. 6 and 7). Moreover, as
was shown at the UPLC spectrum (Fig. 6), EMD386088
seems to be rather a metabolically unstable molecule, because
almost 40% of the compound was metabolized in the presence
of RLMs after 120 min.
The LC/MS analysis provided the accurate molecular
masses of all EMD386088 metabolites which were up from
m/z = 247.26 to m/z = 261.22 corresponding to the
quasimolecular ions [M + H]+ of metabolites M-III and M-
IV or down to m/z = 245.27 (M-I) or m/z = 243.21 (M-II)
(Fig. 7).
The most probable structural formulas of metabolites pro-
posed by MetaSite program were compared with the masses
of pseudomolecular ions from LC/MS analysis. Regarding
obtained by RLMs, the main EMD386088 metabolite M-I,
its molecular mass corresponds to the proposed structure of
M5 (Fig. 4) obtained by the dehydrogenation of
tetrahydropyridine moiety. The molecular mass of metabolite
M-II was not found in in silico data, however, this metabolite
seems to be the effect of succeeding dehydrogenation of me-
tabolite M-I (Fig. 8).
The molecular masses of metabolites M-III and M-IV cor-
respond to the predicted in silico structures of M1, M6, and
M10 (Fig. 4) which are the effect of EMD386088 oxygenation
either in the methyl substituent or in the tetrahydropyridine
moiety.
Effect of EMD386088 on CYP3A4 and CYP2D6 activity
The additional study was performed to determine the effect of
EMD386088 on CYP3A4 and 2D6 activity. The strong
CYP3A4 inhibitor ketoconazole (KE IC50 = 0.1 μM), and
strong CYP2D6 inhibitor quinidine (QD IC50 = 0.01 μM)
Table 2 Pharmacokinetic
parameters for EMD386088
administered alone or jointly with
imipramine (IMI) in rats
Parameters Dose [mg/kg]
EMD386088 2.5 EMD386088 5 EMD386088 2.5 + IMI 15
AUC0 → t [ng ⋅ min/mL] 2210.6 4527.4 7505.5
t1/2[min] 67.3 64.9 77.1
MRT [min] 78.7 78 92.8
Cmax [ng/mL] 22.9 45.2 49
tmax [min] 5 5 60
Vd/F [mL/kg] 102,183.9 97,140.3 32,204.7
Cl/F [mL/min/kg] 1052.6 1038.8 289.4
EMD386088 and imipramine were injected i.p.
AUC area under the curve, t0.5 terminal half-life, Cmax maximum plasma concentration, tmax time to Cmax, Vd/F
apparent volume of distribution, Cl/F apparent systemic clearance, MRT mean residence time
Fig. 2 Concentration-time profile of EMD386088 in plasma (a) and the
brain (b) administered alone or jointly with imipramine (IMI) in rats
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were used as references. EMD386088 did not influence
CYP3A4 activity, and was determined as a very weak
CYP2D6 inhibitor (EMD386088 IC50 = 2.25 μM) (Fig. 9).
Thus, the effect of EMD386088 on CYPs 3A4/2D6 may be
rather excluded as a potential reason responsible for the ob-
served activity of EMD386088 co-administered with
antidepressants.
Discussion
The major finding of the present study was that the inactive
dose of a partial agonist of 5-HT6 receptor EMD386088 co-
administered with an inactive dose of some antidepressants
(i.e., imipramine, moclobemide, reboxetine, and bupropion)
induced pronounced anti-immobility effects in rats. Only dur-
ing coadministration of inactive doses of EMD386088 and s-
citalopram antidepressant-like activity in FST has not been
observed. Moreover, all the above-described positive interac-
tions seem to be specific, since there was no increase in ex-
ploratory activity of rats after administration of the investigat-
ed compounds (single or combined).
The FST is the most extensively used behavioral procedure
for detecting the potential antidepressant activity of com-
pounds. The modified version of FST has been shown to
reliably detect the antidepressant activity of selective seroto-
nin reuptake inhibitors (SSRIs) as well as other compounds
that produce their effects by activating the 5-HT system
Table 3 Distribution of
EMD386088 administered alone
or jointly with imipramine (IMI)
in rats’ brain
Parameters Dose [mg/kg]
EMD386088 2.5 EMD386088 5 EMD38688 2.5 + IMI 15
AUC0 → t [ng ⋅ min/g] 41,936.2 84,462.8 56,428.6
MRT [min] 114 114.8 127.2
Cmax [ng/g] 321 640.3 276.9
tmax [min] 120 120 120
EMD386088 and imipramine were injected i.p.
AUC area under the curve; MRT mean residence time; Cmax maximum plasma concentration; tmax time to Cmax
Fig. 3 The plot of MetaSite predictions for sites of metabolism of
EMD386088
Fig. 4 EMD386088 metabolites
ranking generated by MetaSite
software
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(Detke et al. 1995; Cryan et al. 2005). The modified FST
showed that swimming behavior was increased by SSRIs,
while climbing behavior was increased by antidepressants
with a selective impact on catecholamine transmission
(Detke et al. 1995; Cryan et al. 2005). The most potent
antidepressant-like activity in FST was observed after
Fig. 5 Structures of 10 most probably (scores > 50%) metabolites of EMD386088 generated by MetaSite software
Fig. 6 The UPLC spectra after 30 and 120 min reaction of EMD386088 with RLMs. UPLC ultra-performance liquid chromatography, RLMs rat liver
microsomes
Naunyn-Schmiedeberg's Arch Pharmacol (2018) 391:37–49 45
coadministration of non-active doses of EMD386088 and
imipramine (a significant increase in the climbing behavior
and a decrease in immobility, compared to single administra-
tion as well as to control group). Imipramine acts as a non-
selective 5-HT and noradrenaline reuptake inhibitor (Schloss
and Williams 1998; Slattery et al. 2004). Our previous study
has revealed that EMD386088 did not show any significant
effect on 5-HT and its intraneuronal metabolite (5-
hydroxyindoleacetic acid) concentrations in brain structures
(striatum, nucleus accumbens, and hippocampus) of different
rats. Moreover, Ward et al. (1995) found a 5-HT6 receptor
mRNA in 5-HT projection fields rather than in region contain-
ing cell bodies, which suggests post-synaptical localization of
5-HT6 receptors, and Gérard et al. (1996) reported that 5-HT6
receptors are located outside 5-HT neurons. Our results are in
line with above-presented data. Activation of 5-HT6 receptors
by EMD386088 does not promote the antidepressant-like ac-
tivity of s-citalopram in rats.
Besides the serotonergic and noradrenergic neurotrans-
mission, the dopaminergic pathways may also be involved
in the pathomechanism of depression (Randrup and
Braestrup 1977). This system is associated with serotoner-
gic, GABAergic, cholinergic, and glutamatergic neuro-
transmission and interactions between them contribute to
changes in their mutual signaling. Our previous neuro-
chemical data from ex vivo experiments as well as behav-
ioral data showed that anti-immobility activity of
EMD386088 may be connected with the activation of do-
paminergic system, while neither noradrenergic nor sero-
tonergic systems are involved in its effect. EMD386088
also possesses a significant affinity for dopamine
Fig. 7 MS spectra of EMD386088 and its metabolites in the total ion chromatogram after 120 min of incubation with RLMs. MS mass spectrometer,
RLMs rat liver microsomes
Fig. 8 Proposed structure of metabolite M-II of EMD386088
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transporter, which may be the mechanism responsible for
the abovementioned effect (Jastrzębska-Więsek et al.
2016). Thus, the most effective activity observed for co-
administration of the 5-HT6 receptor partial agonist and
imipramine depends on the involvement of three neuro-
transmitter systems, i.e., dopaminergic from EMD386088
side and serotonergic and noradrenergic from imipramine
side unless pharmacokinetic interaction plays an impor-
tant role here.
Pharmacokinetic drug–drug interaction occurs when
one drug changes the concentration of another by affecting
its absorption, distribution, metabolism, or excretion
(Corrie and Hardman 2014). To the best of our knowledge,
there are no literature data about pharmacokinetic proper-
ties of EMD386088. Therefore, to evaluate the physical
properties of EMD386088 and its interaction with imipra-
mine, some pharmacokinetic parameters as well as brain
and serum concentrations of both compounds, adminis-
tered i.p. to rats, were determined. The pharmacokinetic
study in vivo has revealed a rapid absorption of
EMD386088 and a large volume of distribution, which
indicates its penetration into the peripheral compartments
after i.p. administration. Furthermore, EMD386088 admin-
istered individually penetrates the blood–brain barrier with
a high brain/plasma ratio. These data are in line with the
present and our previous findings. A dose of 2.5 mg/kg is
not active in the FST and produced a lower brain concen-
tration in the brain of rat. Our earlier data indicated that
EMD386088 at a dose of 5 mg/kg i.p. exerts an
antidepressant-like effect in the FST in rats (Jastrzębska-
Więsek et al. 2015). This has been confirmed by at least a
double increase in the concentration of EMD386088 in
brain. Coadministration of EMD386088 and imipramine
resulted in a slower absorption of the compound, decrease
in the volume of distribution, and decrease in penetration
by 2.5 fold.
Most of the isoenzymes of cytochrome P450 are in-
volved in the metabolism of antidepressant drugs, especial-
ly CYP3A4 and CYP2D6 (Spina et al. 2008). Hence, if
changes in the brain concentration of an antidepressant
are observed after coadministration with another drug,
there might be an inhibition of enzymes involved in the
biotransformation. But, the in silico and in vitro studies
on the metabolic stability of EMD386088 showed the de-
hydrogenation of tetrahydropyridine moiety as its main
metabolic pathway. Furthermore, EMD386088 did not in-
fluence on CYP3A4 activity, and has been classified as a
very weak CYP2D6 inhibitor. Moreover, no increase in
brain concentration of imipramine+EMD386088 was not-
ed. The increase in antidepressant-like activity of these
drugs was most likely related to another possibility.
EMD386088 was characterized with a very high perme-
ability for the brain. It is well documented that amphiphilic
or basic (pKa > 8) lipophilic drugs are extensively metab-
olized and can be taken up by acidic compartments like
lysosomes. Lysosomes constitute the largest and the most
important acidic cell compartment (pH = 4–5) and play a
significant role in pharmacokinetics. Weak bases in non-
ionized state diffuse through biological membranes and
accumulate in the acidic interior of lysosomes, where they
are protonated and become unable to diffuse back into
cytosol, which leads to the accumulation of a drug
(Walczak 2013). Lysosomes are present in lungs, liver,
kidneys, spleen, leukocytes, and macrophages and in
smaller quantities in the brain, heart, muscles, and adipose
tissue. The process of lysosomal trapping is saturable, en-
ergy-dependent, and requires cellular integrity. In the pres-
ent study, coadministration of EMD386088 with imipra-
mine decreases the compound permeability to brain.
Imipramine is known as an inhibitor of lysosomal trapping
(Daniel and Wojcikowski 1999). A substantial decrease of
EMD386088 concentration in lysosomes (depot form) ob-
served in vivo leads to an increase in its plasma concentra-
tion which, in turn, decreases the compound’s volume of
distribution.
Conclusions
In summary, the activation of 5-HT6 receptor may facili-
tate antidepressant-like activity of some antidepressants,
whose mechanism of ac t ion is connec ted wi th
Fig. 9 Effects of EMD386088 on
recombinant humanCYP3A4 and
2D6 P450 cytochromes activity
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dopaminergic and noradrenergic transmission. The effect
of EMD386088 on CYP3A4 and CYP2D6 may be rather
excluded as a potential reason responsible for the ob-
served interactions. The distribution kinet ics of
EMD386088 is driven by the compound lipophilicity
and uptake into lysosomes, and these phenomena provide
a possible basis for the compound interaction with other
drugs, e.g., antidepressants in preclinical studies.
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